Logo image of SWTX

SPRINGWORKS THERAPEUTICS INC (SWTX) Stock Fundamental Analysis

NASDAQ:SWTX - Nasdaq - US85205L1070 - Common Stock - Currency: USD

58.25  -1.68 (-2.8%)

After market: 59.3 +1.05 (+1.8%)

Fundamental Rating

4

Taking everything into account, SWTX scores 4 out of 10 in our fundamental rating. SWTX was compared to 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SWTX as it has an excellent financial health rating, but there are worries on the profitability. SWTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SWTX had negative earnings in the past year.
In the past year SWTX has reported a negative cash flow from operations.
In the past 5 years SWTX always reported negative net income.
SWTX had a negative operating cash flow in each of the past 5 years.
SWTX Yearly Net Income VS EBIT VS OCF VS FCFSWTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

SWTX has a Return On Assets (-45.19%) which is in line with its industry peers.
With a decent Return On Equity value of -51.66%, SWTX is doing good in the industry, outperforming 64.65% of the companies in the same industry.
Industry RankSector Rank
ROA -45.19%
ROE -51.66%
ROIC N/A
ROA(3y)-42.42%
ROA(5y)-30.05%
ROE(3y)-47.6%
ROE(5y)-33.33%
ROIC(3y)N/A
ROIC(5y)N/A
SWTX Yearly ROA, ROE, ROICSWTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -10 -20 -30 -40 -50

1.3 Margins

SWTX has a Gross Margin of 94.52%. This is amongst the best in the industry. SWTX outperforms 95.38% of its industry peers.
The Profit Margin and Operating Margin are not available for SWTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SWTX Yearly Profit, Operating, Gross MarginsSWTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

8

2. Health

2.1 Basic Checks

SWTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SWTX Yearly Shares OutstandingSWTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
SWTX Yearly Total Debt VS Total AssetsSWTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 31.93 indicates that SWTX is not in any danger for bankruptcy at the moment.
SWTX has a better Altman-Z score (31.93) than 96.09% of its industry peers.
There is no outstanding debt for SWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 31.93
ROIC/WACCN/A
WACC9.44%
SWTX Yearly LT Debt VS Equity VS FCFSWTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 6.16 indicates that SWTX has no problem at all paying its short term obligations.
SWTX has a Current ratio of 6.16. This is in the better half of the industry: SWTX outperforms 61.99% of its industry peers.
A Quick Ratio of 6.02 indicates that SWTX has no problem at all paying its short term obligations.
SWTX's Quick ratio of 6.02 is fine compared to the rest of the industry. SWTX outperforms 60.75% of its industry peers.
Industry RankSector Rank
Current Ratio 6.16
Quick Ratio 6.02
SWTX Yearly Current Assets VS Current LiabilitesSWTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

SWTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.43%, which is quite impressive.
EPS 1Y (TTM)32.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1029.98%

3.2 Future

Based on estimates for the next years, SWTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.97% on average per year.
SWTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.72% yearly.
EPS Next Y40.43%
EPS Next 2Y31.45%
EPS Next 3Y51.07%
EPS Next 5Y14.97%
Revenue Next Year81.6%
Revenue Next 2Y71.1%
Revenue Next 3Y72.81%
Revenue Next 5Y46.72%

3.3 Evolution

SWTX Yearly Revenue VS EstimatesSWTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
SWTX Yearly EPS VS EstimatesSWTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SWTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SWTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SWTX Price Earnings VS Forward Price EarningsSWTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SWTX Per share dataSWTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as SWTX's earnings are expected to grow with 51.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.45%
EPS Next 3Y51.07%

More info and screens

0

5. Dividend

5.1 Amount

SWTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPRINGWORKS THERAPEUTICS INC

NASDAQ:SWTX (2/21/2025, 8:00:01 PM)

After market: 59.3 +1.05 (+1.8%)

58.25

-1.68 (-2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20/bmo
Earnings (Next)04-30 2025-04-30/bmo
Inst Owners105.55%
Inst Owner Change7.96%
Ins Owners2.14%
Ins Owner Change-3.35%
Market Cap4.33B
Analysts85.71
Price Target73.36 (25.94%)
Short Float %20.31%
Short Ratio7.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.36%
Min EPS beat(2)6.2%
Max EPS beat(2)52.52%
EPS beat(4)3
Avg EPS beat(4)11.35%
Min EPS beat(4)-14.6%
Max EPS beat(4)52.52%
EPS beat(8)7
Avg EPS beat(8)8.45%
EPS beat(12)7
Avg EPS beat(12)0.16%
EPS beat(16)8
Avg EPS beat(16)20.83%
Revenue beat(2)1
Avg Revenue beat(2)30.71%
Min Revenue beat(2)-9.1%
Max Revenue beat(2)70.52%
Revenue beat(4)3
Avg Revenue beat(4)145.64%
Min Revenue beat(4)-9.1%
Max Revenue beat(4)456.27%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.82%
PT rev (3m)-0.93%
EPS NQ rev (1m)1.23%
EPS NQ rev (3m)32.28%
EPS NY rev (1m)1.69%
EPS NY rev (3m)8.12%
Revenue NQ rev (1m)-2.79%
Revenue NQ rev (3m)18.78%
Revenue NY rev (1m)1.61%
Revenue NY rev (3m)-0.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.98
P/FCF N/A
P/OCF N/A
P/B 8.14
P/tB 8.14
EV/EBITDA N/A
EPS(TTM)-3.48
EYN/A
EPS(NY)-2.07
Fwd EYN/A
FCF(TTM)-2.97
FCFYN/A
OCF(TTM)-2.81
OCFYN/A
SpS1.82
BVpS7.16
TBVpS7.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.19%
ROE -51.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.52%
FCFM N/A
ROA(3y)-42.42%
ROA(5y)-30.05%
ROE(3y)-47.6%
ROE(5y)-33.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 413.12%
Cap/Sales 9.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.16
Quick Ratio 6.02
Altman-Z 31.93
F-Score5
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)726.64%
Cap/Depr(5y)543.08%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.28%
EPS Next Y40.43%
EPS Next 2Y31.45%
EPS Next 3Y51.07%
EPS Next 5Y14.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1029.98%
Revenue Next Year81.6%
Revenue Next 2Y71.1%
Revenue Next 3Y72.81%
Revenue Next 5Y46.72%
EBIT growth 1Y8.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.62%
EBIT Next 3Y17.34%
EBIT Next 5YN/A
FCF growth 1Y-35.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.87%
OCF growth 3YN/A
OCF growth 5YN/A